Unlocking Opportunities in the G-CSF (Granulocyte Colony Stimulating Factors) Market: 2025-2034 Forecast Report

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

G-CSF (Granulocyte Colony Stimulating Factors) Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market size for G-CSF (granulocyte colony stimulating factors) has been on a consistent growth trajectory in the past few years. The market is predicted to expand from $5.5 billion in 2024 reaching up to $5.72 billion by 2025, suggesting a compound annual growth rate (CAGR) of 3.9%. The expansion witnessed during the historic period is tied to factors such as rising cancer rates, robust economic growth in emerging markets, an uptick in healthcare spending, enhanced investment in pharmaceutical research & development, and governmental initiatives.

G-CSF (Granulocyte Colony Stimulating Factors) Market Size Forecast: What's the Projected Valuation by 2029?
In the coming years, the G-CSF (granulocyte colony stimulating factors) market is anticipated to experience significant expansion, reaching a size of $7.19 billion by 2029 with a compound annual growth rate (CAGR) of 5.9%. The expected progress over the forecasting period is linked to factors such as higher incidences of cancer, amplified demand for prophylaxis granulocyte colony-stimulating factor (g-CSF), elevation in health care expenditures, great potential in up-and-coming economies, advancements in technology, and an increasing presence of biosimilar drugs. Upcoming trends over the forecast period consist of heavy investment in research and development for the creation of effective and innovative medications, growing emphasis on mergers and acquisitions as growth tactics, the formation of strategic collaborations, involvement in the development of new drugs, and a concentrated effort towards biosimilars manufacturing for neutropenia treatment to boost revenue and product range.

View the full report here:
https://www.thebusinessresearchcompany.com/report/g-csf-global-market-report

What Are the Drivers Transforming the G-CSF (Granulocyte Colony Stimulating Factors) Market?
The escalating rates of cancer is a fundamental player propelling expansion in the G-CSF (granulocyte colony stimulating factor) market. Positioned as the second leading cause of mortality, cancer contributes to approximately 1 in 6 deaths globally. As per the American Cancer Society in January 2023, a non-profit in the US committed to cancer eradication, it is estimated that there will be 1,958,310 new cases of cancer and 609,820 deaths from it in the US in 2023. G-CSF, a type of growth factor, enhances white blood cell production in the bone marrow, mitigating the possibility of infections and sepsis. In those with cancer, it augments recovery, decreases death rates from neutropenia following chemotherapy, and curbs infections post-certain cancer treatments. Thus, the rising incidence of cancer is forecasted to fuel the development of the G-CSF market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3466&type=smp

What Long-Term Trends Will Define the Future of the G-CSF (Granulocyte Colony Stimulating Factors) Market?
Businesses operating in the G-CSF (granulocyte colony stimulating factor) market are concentrating on strategic alliances to create novel products and expand their market reach. In recent years, collaboration has been on the rise in this sector, with corporations entering partnerships and both in and out-licensing deals with fellow businesses and academic and research entities. A case in point is Evive Biotech, a Singapore-based biopharmaceutical company which, in 2022, formed an exclusive long-term licensing agreement with Germany's APOGEPHA for the sale of Efbemalenograstim alfa (F-627) in Germany and Switzerland. F-627 represents an innovative dimeric G-CSF long-acting fusion protein which doesn't entail pegylation.

Which Segments in the G-CSF (Granulocyte Colony Stimulating Factors) Market Offer the Most Profit Potential?
The G-CSF (granulocyte colony stimulating factors) market covered in this report is segmented -

1) By Type: Pegfilgrastim, Lenograstim, Filgrastim, Other Types
2) By Product: Tablet, Capsule, Other Products
3) By Application: Oncological Diseases, Blood Disorders, Chronic And Autoimmune Disorders, Other Applications

Subsegments:
1) By Pegfilgrastim: Pre-filled Syringes, Vial Formulations, Biosimilars Of Pegfilgrastim
2) By Lenograstim: Injectable Formulations, Vial Formulations, Combination Therapies
3) By Filgrastim: Injectable Formulations, Pre-filled Syringes, Biosimilars Of Filgrastim
4) By Other Types: Filgrastim-sndz (Biosimilar), Novel G-CSF Products In Development, Combination Therapies With Other Growth Factors

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=3466&type=smp

Which Firms Dominate the G-CSF (Granulocyte Colony Stimulating Factors) Market by Market Share and Revenue in 2025?
Major companies operating in the G-CSF (granulocyte colony stimulating factors) market include Amgen Inc., Coherus Biosciences Inc., Sandoz, Biocon/Mylan, Teva Pharmaceuticals Inc., Chugai Pharma, Intalfarmaco Group, Pfizer, Sun Pharmaceutical Industries Limited, BeyondSpring Inc., Kyowa Hakko Kirin Co. Ltd, BioCad, Stada Arzneimittel, Dong-A Socio Group, Dr. Reddy's Laboratories, Celltrion Inc., Emcure Pharmaceuticals, Accord Healthcare UK, Intas Pharmaceuticals, Spectrum Pharmaceuticals, Apobiologix, Apotex Inc., Eurofarma Laboratórios, BIOPHARMA-MEA, NeoTX, AID Genomics Limited, GlaxoSmithKline plc, AstraZeneca, Merck Sharp & Dohme Corp., Julphar, Sanofi, Novo Nordisk A/S, Bayer, Kitov Pharma Limited, CureTech Ltd., Neopharma, Cipla.

Which Regions Offer the Highest Growth Potential in the G-CSF (Granulocyte Colony Stimulating Factors) Market?
North America was the largest region in the G-CSF (granulocyte colony-stimulating factors) market in 2024. The regions covered in the G-CS (granulocyte colony stimulating factors) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3466

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.